The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life.
Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints.
Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart).
The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated.
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively.
The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

开始日期2026-06-01

申办/合作机构

University Hospitals Cleveland Medical Center

NCT06928246

/ Not yet recruiting临床1期IIT

Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

开始日期2025-07-01

申办/合作机构

University of Pittsburgh

[+1]

NCT07025642

/ RecruitingN/AIIT

Outcome of Different Treatments of Overactive Bladder in Taiwan

Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition.
To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters.
Furthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance.
Comparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms.
To extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting.
In summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.

开始日期2025-07-01

申办/合作机构

Mackay Medical College

100 项与 A型肉毒毒素相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素相关的专利（医药）

登录后查看更多信息

5,314

项与 A型肉毒毒素相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Systematic review of pharmacotherapy for atypical facial pain: evaluation of pain reduction, depression, anxiety and quality of life

Review

作者: Alshammari, Sattam S. ; Alassaf, Hind M. ; Alqarni, Ali A. ; Abed, Hassan H. ; Shaikh, Sameer ; Alkurdi, Khlood A. ; Alshammari, Abdullah F. ; Alshammary, Freah L. ; Madfa, Ahmed A.

BACKGROUND/PURPOSE:

Atypical facial pain (AFP) is a chronic condition characterized by persistent facial pain without clear clinical signs, making diagnosis and treatment difficult. Common pharmacological treatments include antidepressants, anticonvulsants and neuromodulators, but their effectiveness remains uncertain, necessitating a systematic review to guide clinical practice.

MATERIALS AND METHODS:

Following PRISMA 2020 guidelines, randomized controlled trials (RCTs) evaluating pharmacological treatments for AFP in adults were included. A comprehensive search of five databases without date restrictions was performed. Data on pain reduction, quality of life, and adverse events were extracted. The Cochrane Risk of Bias (RoB 2.0) tool assessed bias, and evidence quality was evaluated using the Critical Appraisal Skills Programme tool.

RESULTS:

Out of 196 studies identified, 10 RCTs met the inclusion criteria. Pharmacological responses varied significantly across studies. Antidepressants such as dothiepin and clomipramine demonstrated significant pain reduction, whereas venlafaxine showed limited efficacy. However, onabotulinum toxin A and sumatriptan exhibited inconsistent or minimal effects on AFP pain intensity. Adverse events were reported across multiple treatments, ranging from mild side effects such as dry mouth and nausea to severe reactions like diplopia and facial asymmetry, which impacted adherence. Despite some positive outcomes, the heterogeneity in study methodologies, outcome measures, and follow-up durations limited direct comparisons between interventions.

CONCLUSION:

This systematic review highlights the mixed efficacy of pharmacological treatments for AFP, with certain medications demonstrating superior pain relief in specific patient subgroups. Given the variability in response and adverse events, a multimodal approach combining pharmacological and non-pharmacological therapies may offer the most effective management strategy. Future research should focus on standardized treatment protocols, long-term efficacy, and personalized treatment plans to optimize patient care.

2025-12-01·Techniques in Coloproctology

Management of chronic anal fissures: should fissurectomy be performed with botulinum toxin injection?

Article

作者: Albayati, S ; Ellis-Clark, J ; Quinn, R

Abstract:

Background:

Despite the superior success rate of lateral internal sphincterotomy for managing chronic anal fissure (CAF), there is a trend towards sphincter-preserving treatment due to the increased risk of incontinence. Botulinum toxin (BT) and fissurectomy are two sphincter-preserving options for CAF. We aim to assess if combining fissurectomy with botox treatment is superior to botulinum toxin alone in the management of CAF.

Methods:

This retrospective cohort study was conducted across two Sydney hospitals over 7 years. All patients with a CAF managed with either BT and fissurectomy (group 1) or BT only (group 2) were included. Primary outcome was healing rate defined as resolution or significant improvement of perianal symptoms at initial follow-up. Secondary outcomes were persistence, recurrence, re-intervention and faecal incontinence rate. Follow-up questionnaire was conducted to compare long-term outcomes between the two groups.

Results:

Fifty-seven patients met the inclusion criteria (group 1, 37; group 2, 20). Mean BT dose and injection location between the groups were similar (p = 0.259 and p = 0.427). There was a 65% response rate to the follow-up questionnaire. Median follow-up was 34.3 months (range 0.4–93). There was no difference in healing (56.7% vs. 50%, p = 0.561), recurrence (37.8% vs. 30%, p = 0.383) or re-intervention rate (13.5% vs. 20%, p = 0.888). Long-term incontinence rate was significantly higher in patients group 2 (0% vs. 10%, p = 0.010), with two patients reporting persistent flatus incontinence. Median overall satisfaction score was 3/4 (range 1–4), in both groups (p = 0.469).

Conclusion:

Botulinum toxin with or without fissurectomy is a safe sphincter-sparing treatment option for CAF. However, the addition of fissurectomy to BT does not improve healing rates and we therefore recommend BT injection alone as a second-line treatment of CAF in patients who fail topical treatment.

2025-12-01·Current Pain and Headache Reports

Prognostic Value of Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Profiles in Predicting Outcomes of Occipital Nerve Stimulation for Refractory Chronic Migraine: A Retrospective Bias-Corrected Multivariable Analysis

Review

作者: Naccarato, Alessia ; Varrassi, Giustino ; Viswanath, Omar ; Arcioni, Roberto ; Sarmi, Samah Said Al ; Leoni, Matteo Luigi Giuseppe ; Mercieri, Marco ; Cascella, Marco

Abstract:

Background:

Refractory chronic migraine (rCM) is characterized by debilitating headaches that do not respond adequately to conventional medical treatments, leaving patients severely disabled. In these rare cases, central cervical spinal cord stimulation or occipital nerve stimulation (ONS) may offer a potential therapeutic option. However, these techniques are not without risks, lack clear scientific evidence, and impose a significant economic burden. Therefore, it is crucial to identify parameters that can assist physicians in selecting appropriate candidates for implantation. This study aimed to investigate the role of psychological profiles in predicting outcomes for ONS in rCM patients.

Methods:

We conducted a retrospective analysis on rCM patients treated with ONS at a second-level neuromodulation university facility. These patients were refractory to conventional medical treatments, including onabotulinumtoxin-A injections (monoclonal antibodies targeting CGRP were not yet available). The NRS for migraine intensity, the number of monthly migraine attacks, and drug consumption were assessed at 6-month and 12-month follow-ups post-implant. Psychological profiles were evaluated prior to OCN using the Minnesota Multiphasic Personality Inventory-2 (MMPI-2). A multivariable logistic regression model was developed to predict ONS outcomes, incorporating MMPI-2 as a covariate. The model’s accuracy and performance were assessed through non-parametric bootstrap, calibration, and discrimination analyses.

Results:

Twenty-three rCM patients were analysed. ONS was able to significantly reduce the pain intensity, the number of headache attacks per month, and drug consumption compared to pre-treatment levels at both 6- and 12-month follow-ups. The final multivariable logistic model at 12 months showed that the MMPI-2 Depression score was independently and negatively associated with favourable outcomes following ONS (optimism-adjusted OR 0.52, 95% CI 0.21–0.77, p = 0.03). The ROC curve indicated high model sensitivity (AUC: 0.96, 95% CI: 0.88–0.98), and the calibration plot revealed a good fit, with some improvement needed in mid-range predicted probabilities.

Conclusion:

ONS significantly reduced pain intensity, headache frequency, and drug use at the 12-month follow-up compared to pre-treatment levels. The MMPI-2 Depression score was an independent predictor of ONS failure, highlighting the importance of comprehensive psychological assessments in patient selection for ONS.

399

项与 A型肉毒毒素相关的新闻（医药）

2025-07-22

·FiercePharma

AbbVie wins $56M royalty award from Revance in Botox patent infringement case

In a four-year-old case, AbbVie has triumphed over Revance Therapeutics as a Delaware jury has agreed that the Nashville, Tennessee-based company infringed three patents in creating Botox rival Daxxify and has awarded a $56 million royalty payment. AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic treatment Botox. Now, the companies have extended their dominance to the courtroom.A Delaware jury has agreed with AbbVie’s claim that in creating a rival treatment for Botox, Revance Therapeutics infringed three patents covering the formulation and manufacturing process of the megablockbuster. With the verdict, the jury awarded (PDF) a royalty payment of $56 million from Revance to AbbVie.In rejecting Revance’s claim that the patents were invalid, the jury assigned royalty rates of 15% on one patent that remains ongoing and 12% and 4% on patents that expired in September 2023. The royalties are to be paid on sales of Revance’s Botox rival Daxxify, which was approved in 2022 and accumulated revenue of $84 million in 2023 and $79 million in the first three quarters of last year.In August of last year, private skin care company Crown Laboratories bought out Nashville, Tennessee-based Revance for $924 million. AbbVie, which acquired Allergan for $63 billion in 2020, filed its lawsuit against Revance the following year, asking for “reasonable royalty and lost profits.”In 2023, AbbVie filed another lawsuit against Revance, claiming the company recruited key employees as part of a strategy to get its hands on proprietary information. The Illinois pharma giant characterized Revance’s tactics to compete as “desperate” and said the rival company has “taken shortcuts by misappropriating trade secrets.” Botox has been a blockbuster since 2006 and topped the $2 billion mark in 2016. Last year, revenue from Botox reached $6 billion, with worldwide therapeutic sales ($3.3 billion) exceeding cosmetic sales ($2.7 billion).

并购专利侵权

2025-07-11

·PRNewswire

The Inner Circle acknowledges, Carolyn W. Quist, DO, FACOOG as a Pinnacle Lifetime Member

FORT WORTH, Texas, July 11, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Carolyn W. Quist, DO, FACOOG is acknowledged as a Pinnacle Lifetime Member for her contributions as a Leading Advocate for Women's Health and Well-being. Dr. Carolyn W. Quist, a renowned osteopathic gynecologist, credits much of her success to the guidance and support of her mentors, Dr. John Chapman, DO, and Dr. Steve Buchanan, DO. She also acknowledges Dr. Ronald Ayres and Dr. Ron Librizzi as instrumental in her professional development, providing invaluable support and influence throughout her career. Continue Reading Carolyn W. Quist, DO, FACOOG With a focus on hormone replacement therapy and aesthetic procedures, Dr. Quist's expertise and commitment to excellence have made her a trusted healthcare provider in her community. She earned her Bachelor of Science in pre-medical studies from the University of Texas at Arlington before completing her Doctor of Osteopathic Medicine Degree from the University of North Texas Health Science Center–Texas College of Osteopathic Medicine. She has also been involved with the American Osteopathic Association for many years and is currently chair of the Bureau of Osteopathic Specialists. As the medical director for Revitalize Wellness Center, PA, Dr. Quist oversees a range of aesthetic procedures, including vaginal therapy, Botox treatments, peptides, and hair loss treatments. She is dedicated to helping women look and feel their best, offering treatments that enhance both their physical appearance and overall well-being. Her staff now includes a certified nurse practitioner specializing in family medicine, whose addition has been invaluable in providing comprehensive services to her patients. Throughout her career, Dr. Quist has been dedicated to promoting women's health and well-being. She provides routine gynecology care, hormone therapy, and aesthetic treatments to address a variety of women's health issues, including menopause management and sexual dysfunction treatments. Outside of her medical practice, Dr. Quist enjoys scuba diving and vacationing in the Caribbean. She has participated in mission trips to Cambodia and Jordan through Christ Chapel Bible Church and has been active in disaster relief ministry in hurricane-affected areas of Louisiana and Texas, reflecting her deep commitment to philanthropy and community service. Dr. Quist's philosophy centers on providing compassionate care, continuous learning, and giving back to the community through philanthropic efforts and involvement with charitable organizations. In the future, she aims to continue her commitment to excellence in women's health care, expanding her practice, and staying actively engaged in philanthropy and community service. SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2025-07-08

·ir.dermatarx.com

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / July 8, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced the Australian Patent Office has granted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Australian Patent No. 2109284621) continues to strengthen Dermata's global intellectual property portfolio for DMT410 for the treatment of hyperhidrosis. "We are thrilled to be granted this Australian patent, a testament to our team's relentless innovation and dedication to providing patients with unique and novel treatment options," said Gerry Proehl, Dermata's Chairman, President, and CEO. "We believe this patent reinforces our commitment to pushing boundaries for standard of care for hyperhidrosis patients and delivering groundbreaking solutions that we believe can transform the lives of patients. We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis, as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis, which remain high unmet needs for patients," Mr. Proehl added. About DMT410 DMT410 is the Company's combination treatment regimen that uses the unique mechanical features of the Company's XYNGARI™ product candidate to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle. The treatment consists of an initial topical application of XYNGARI™ to the treatment area where the microscopic spicules penetrate the stratum corneum to create microchannels into the dermis allowing for the topical application and penetration of botulinum toxin. The Company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis and for the treatment of multiple aesthetic skin conditions. Both studies showed promising efficacy results and appeared to be safe and well tolerated by patients. The Company is also planning to initiate a Phase 2a study of DMT410 (XYNGARI™ with DAXXIFY®) for the treatment of axillary hyperhidrosis. About Dermata Therapeutics Dermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications. Dermata's lead product candidate, XYNGARI™ (formerly DMT310), is its first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action that recently achieved positive data in a Phase 3 STAR-1 study for the treatment of moderate-to-severe acne. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. Dermata's second program, DMT410, uses XYNGARI™ as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin diseases and conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies, including the FDA; the uncertainties inherent in clinical trials; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidate DMT410 development activities and ongoing and planned clinical trials; whether the results of any planned clinical trials of DMT410 will lead to future product development; whether pending patent applications will proceed to allowance without interruption, if at all; and whether pending, accepted, or issued patents will provide adequate protection for the Company's product candidates, if approved. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. Investors: Cliff Mastricola Investor Relations cmastricola@dermatarx.com SOURCE: Dermata Therapeutics Released July 8, 2025

临床结果临床1期临床3期

100 项与 A型肉毒毒素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08957	A型肉毒毒素	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
咀嚼肌肥大	中国	Allergan, Inc.	2024-06-03
肌张力失调	美国	AbbVie, Inc.	2022-08-22
神经源性逼尿肌过度活动	美国	AbbVie, Inc.	2022-08-22
尿失禁	美国	AbbVie, Inc.	2022-08-22
发声困难	日本	GSK Plc	2018-05-25
额头皱纹	美国	AbbVie, Inc.	2017-10-02
膀胱功能障碍	美国	AbbVie, Inc.	2017-04-04
外眦皱纹	美国	AbbVie, Inc.	2013-09-11
上下肢痉挛	美国	AbbVie, Inc.	2010-03-09
马蹄状畸形	日本	Allergan, Inc.	2009-01-21
多汗症	日本	Allergan, Inc.	2009-01-21
偏头痛	日本	-	2009-01-21
皮肤疾病	日本	Allergan, Inc.	2009-01-21
神经性膀胱功能障碍	日本	Allergan, Inc.	2009-01-21
膀胱过度活动症	日本	Allergan, Inc.	2009-01-21
原发性颈性肌张力障碍	日本	GSK Plc	2005-10-03
肌肉痉挛	-	Genesis Healthcare, Inc.	2005-10-03
原发性腋窝多汗症	美国	AbbVie, Inc.	2004-07-19
斜视	美国	AbbVie, Inc.	2004-07-19
眼睑痉挛	中国	Allergan Pharmaceuticals Ireland ULC	2003-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	加拿大	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	捷克	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	德国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	以色列	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	波兰	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	西班牙	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	瑞典	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	英国	AbbVie, Inc.	2021-11-05
无先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04609020 (CTgov)	临床4期	皮肤疾病 \| 皮肤起皱	64	Lidocaine+BOTOX	鬱遞淵鬱蓋鑰範獵鏇積(顧選構壓壓鹽鹽齋廠願) = 淵範鏇獵願鬱願蓋選餘壓願淵餘鹽積窪憲糧鬱 (鬱壓選觸衊壓鹹蓋簾製, 23.61) 更多	-	2025-06-17
NCT04965311 (CTgov)	临床2期	胰腺瘘 \| 胰腺癌	4	Botulinum Toxin Type A	窪餘願廠鹽淵壓窪願鏇 = 鹹艱夢艱淵窪構製淵獵選窪構築膚繭窪憲鹹鏇 (觸淵夢蓋選衊選積鬱夢, 憲餘壓積鹽鹹襯醖繭選 ~ 築選簾鏇顧築壓鑰遞廠) 更多	-	2025-05-13
NCT04073303 (CTgov)	临床3期	-	377	Placebo	選餘夢繭積繭遞遞築廠 = 糧衊醖範夢獵醖選製艱構網蓋壓蓋糧選艱夢壓 (糧壓願範餘鑰鹹顧選觸, 鏇簾齋鏇糧構願壓糧夢 ~ 憲積窪膚窪觸遞襯壓製) 更多	-	2025-05-06
P9-2.012 (AAN2025)	N/A	偏头痛 \| 肌张力障碍	-	Botulinum Neurotoxin (CD+migraine/headache patients)	窪夢鑰網衊糧鑰艱窪選(鹹繭願遞鏇壓壓遞觸遞) = 膚遞糧願鏇襯製願鑰鑰夢觸願築壓憲遞積醖鑰 (遞繭獵網襯鏇膚糧構憲 )	-	2025-04-07
P9-2.012 (AAN2025)	N/A	偏头痛 \| 肌张力障碍	-	Botulinum Neurotoxin (CD+CM patients)	窪夢鑰網衊糧鑰艱窪選(鹹繭願遞鏇壓壓遞觸遞) = 選鹽繭鏇選鹽遞襯獵築夢觸願築壓憲遞積醖鑰 (遞繭獵網襯鏇膚糧構憲 )	-	2025-04-07
NCT04171531 (MUSA, CTgov)	临床3期	压力性尿失禁 \| 急迫性尿失禁	150	Mid-urethral sling	簾壓廠構蓋範餘壓製網(構構夢餘鹹齋憲鹹網糧) = 衊願遞網夢窪艱鹹夢襯簾積壓鹽壓窪廠衊繭鏇 (顧範簾簾憲鹽壓衊範糧, 壓夢蓋醖淵壓網網壓網 ~ 壓簾製憲糧襯憲淵鏇製) 更多	-	2025-03-20
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (1 Injection Site)	築糧願醖衊醖膚獵糧積(憲鬱繭構選膚夢獵鹽淵) = 齋襯獵鹽醖衊簾窪窪選鬱繭網壓鑰鹹網顧簾鬱 (構顧範夢簾網製選餘遞, 26.25) 更多	-	2025-02-14
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (10 Injection Sites)	築糧願醖衊醖膚獵糧積(憲鬱繭構選膚夢獵鹽淵) = 醖製積鏇齋簾糧糧窪鑰鬱繭網壓鑰鹹網顧簾鬱 (構顧範夢簾網製選餘遞, 24.92) 更多	-	2025-02-14
NCT05134649 (CTgov)	临床3期	颈阔肌突出	292	OnabotulinumtoxinA	憲醖鹽願糧艱網糧鹹鬱(範衊繭願構艱鏇範糧糧) = 觸窪鏇憲鹹膚鏇鏇簾鹹鏇憲顧襯遞膚膚鏇鹹餘 (繭積簾鹽製鹹餘膚鏇衊, 蓋壓鹹襯鏇範繭構顧憲 ~ 顧鏇築積醖繭遞製鏇糧) 更多	-	2024-12-05
NCT06080438 (CTgov)	临床4期	多泪 \| 眼睑痉挛	2	Botulinum toxin	窪積醖淵製鬱製膚艱淵(網鹽顧鑰餘壓衊齋夢壓) = 艱選鏇淵繭獵膚築鹽淵觸醖鬱齋憲憲餘鬱觸艱 (夢範簾餘憲遞製獵鹹觸, 0.69) 更多	-	2024-12-05
NCT03456154 (Pubmed \| J Dent)	临床4期	夜磨牙症 \| 肌痛	-	botulinum toxin-a (Occlusal splint)	蓋艱鏇遞膚淵願顧夢鹽(餘範構鑰願壓衊襯鹹糧): OR = 0.29 (95% CI, 0.11 ~ 0.82)	积极	2024-12-01
NCT03456154 (Pubmed \| J Dent)	临床4期	夜磨牙症 \| 肌痛	-	Botulinum toxin-A	蓋艱鏇遞膚淵願顧夢鹽(餘範構鑰願壓衊襯鹹糧): OR = 0.29 (95% CI, 0.11 ~ 0.82)	积极	2024-12-01
NCT04949399 (CTgov)	临床3期	颈阔肌突出	408	Placebo (Placebo)	夢構願壓願網膚鏇醖顧 = 憲顧餘艱願鬱鹽窪襯網壓簾觸鹽壓膚鬱膚願製 (淵繭鏇壓憲鏇淵襯廠範, 鹽製鹽襯鬱憲蓋醖鹹壓 ~ 夢選構糧簾鑰遞簾製顧) 更多	-	2024-11-20
NCT04949399 (CTgov)	临床3期	颈阔肌突出	408	OnabotulinumtoxinA (BOTOX)	夢構願壓願網膚鏇醖顧 = 獵蓋顧鏇遞夢網蓋鬱獵壓簾觸鹽壓膚鬱膚願製 (淵繭鏇壓憲鏇淵襯廠範, 膚獵構鏇壓獵齋築艱選 ~ 醖淵顧鏇遞夢衊製網製) 更多	-	2024-11-20